Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology. Initial therapy for CML remains imatinib, a Novartis drug known as Gleevec®, which has increased the five-year survival rate for the disease from 50 percent to 90 percent of patients. In separate clinical trials, M. D... 
More...
More...